TD Cowen analyst Boris Peaker lowered the firm’s price target on CTI BioPharma to $8 from $10 and keeps an Outperform rating on the shares. The analyst said we are updating our model and corresponding estimates as VONJO sales have been slower than initially anticipated.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CTIC: